Tool: DupCheckTool: DupCheck is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.

Project FlyerProject Flyer

Click here to download 
the NEWMEDS project flyer! 

consortium teaser

Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms

  Members Area

IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

Workpackage 08

Workpackage Objectives

  • Establish predictors of differential response to noradrenergic vs. serotonergic antidepressants using integrative modelling of clinical and genomic variables. This will include candidate gene tests and systematic genome-wide exploration.
  • Establish genomic signature of treatment resistant depression to provide a target group for the development and testing of novel treatments. This will also initially involve candidate genes and then a systematic genome-wide exploration. 
  • Develop and test the sensitivity/specificity of prediction of response at individual level.
  • Characterise the functionality of identified genetic variants associated with response to antidepressants at molecular and system level.

Workpackage Leads

Academic Lead: Prof. Peter McGuffin and Dr. Rudolf Uher, King’s College London, UK
EFPIA Lead: Dr. Jens Robert Wendland, F. Hoffmann - La Roche, Switzerland

Workpackage Partners

  • H. Lundbeck A/S
  • AstraZeneca AB
  • GlaxoSmithKline Research and Development Ltd.
  • Abbott Laboratories 

Synergy between academia and industry

The academy and EFPIA will complement each other in their skills and the type of samples available to them. The team at IoP-KCL has developed considerable expertise in the statistical analysis of pharmacogenetic data in the GENDEP project and of genome-wide data in large-scale case control studies. The GSK contributes expertise in gene set prioritising, based on a database developed by their bioinformatics group led by Dr. Michael R. Barnes. However, the most critical element in NEWMEDS is the pooling of datasets – no single industry or academic site has the ability to bring together data from 6,500 subjects including placebo-treated subjects. This will allow creating one of (if not the) largest combined datasets that will enable a powerful pharmacogenetic analysis, whilst controlling for non-specific factors using the placebo-treated group. Furthermore, the academy- and industry-lead datasets are complementary in many ways: e.g. the academy-led studies may be more inclusive and generalisable, but they lack placebo-control and thus are unable to distinguish predictors of treatment outcome from determinants of prognosis irrespective of treatment.

WP08 - Identifying biomarkers of response and personalized medicine – a focus on depression